Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mediwound ( (MDWD) ) has shared an announcement.
On March 30, 2026, MediWound filed a Form 6-K announcing it had published proxy materials and notice for its 2026 annual general meeting of shareholders, to be held on May 6, 2026 in New York. The meeting will cover the re-election of five directors, the reappointment of Somekh Chaikin (KPMG) as independent auditor for 2026, and shareholder approval of an annual cash bonus for CEO Ofer Gonen for his 2025 performance.
At the meeting, MediWound will also present and discuss its audited consolidated financial statements for the year ended December 31, 2025, previously filed on Form 20-F on March 5, 2026. The Form 6-K further incorporates the meeting materials by reference into multiple existing S-8 and F-3 registration statements, underscoring the governance and disclosure framework relevant to shareholders eligible to vote as of the March 31, 2026 record date.
The most recent analyst rating on (MDWD) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
The score is held down primarily by weak financial performance (shrinking/volatile revenue, large losses, and sustained negative free cash flow) and a technically weak price trend (below key moving averages with negative MACD). The earnings call provides a partial offset via reaffirmed multiyear guidance, manufacturing expansion and trial progress, but execution, funding, and regulatory timing risks remain meaningful; valuation is also constrained by ongoing losses and no dividend yield data.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is an Israel-based biopharmaceutical company listed in the U.S. as a foreign private issuer. The company focuses on developing and commercializing therapies, and it reports to investors via Form 20-F and uses Form S-8 and F-3 registration statements for equity and financing-related activities in the U.S. capital markets.
Average Trading Volume: 99,601
Technical Sentiment Signal: Sell
Current Market Cap: $193.3M
For detailed information about MDWD stock, go to TipRanks’ Stock Analysis page.